7 results
In subjects with T2DM with inadequate glycemic control on combination therapy withmetformin and an SU:Primary:* To assess the effect of the addition of treatment with canagliflozin compared with theaddition of treatment with sitagliptin on HbA1c…
In subjects with T2DM, with inadequate glycemic control, who have a history or high risk of CV disease:Primary Objectives*to assess the effect of canagliflozin plus standard of care relative to placebo plus standard of care on CV risk as measured by…
Primary: Antiviral efficacy of dolutagravir in combination with Kivexa (abacavir en lamivudine) after 48 weeks of treatment in comparison with Atripla (tenofovir, emtricitabine and efavirenz). Secondary: Antiviral efficacy after 96 and 144 weeks,…
Primary objectiveIn subjects with T2DM receiving standard of care but with inadequate glycemic control and at elevatedrisk of cardiovascular (CV) events to assess the effect of canagliflozin compared to placebo onprogression of albuminuria.Secondary…
Primary:To assess the efficacy of DS-1062a, as measured by the ORR, as a treatment for subjects with NSCLC with actionable genomic alterations that has progressed on or after 1platinum-containing therapy and 1 platinum-containing therapy and 1 or…
The main objectives are:• To assess canagliflozin target (i.e. receptor) specific binding in vivo• To assess receptor occupancy of canagliflozin in vivo• To determine optimal scanning time in vivoTo explore the relationship between canagliflozin…
MAIN OBJECTIVES:- To compare the efficacy of Dato-DXd in combination with pembrolizumab versus pembrolizumab alone, as measured by progression-free survival (PFS) by blinded independent central review (BICR).- To compare the efficacy of Dato-DXd in…